Delta4 Secures European Patents for AI-Identified FSGS Treatments

Delta4, a leader in AI-driven drug discovery, has been granted European patents for two innovative compounds positioned as candidate treatments for focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disease. These patents mark a significant milestone in the company's mission to accelerate the delivery of groundbreaking therapies leveraging advanced computational biology. The newly patented compounds include clopidogrel, already approved for cardiovascular conditions, and a novel combination of saroglitazar and myristic acid.

Clopidogrel was identified by Delta4's proprietary AI platform, Hyper-C, as a promising candidate for FSGS. In animal models, clopidogrel demonstrated a 61% reduction in the urinary albumin to creatinine ratio, a critical marker of kidney function, along with significant improvements in histopathological damage with a 67.9% reduction in kidney damage scores. The compound also showed anti-inflammatory, anti-fibrotic, and immune-modulating effects, addressing key mechanisms of FSGS progression.

The Saro+Myr combination leverages the dual PPAR agonist properties of saroglitazar and the calcineurin-inhibiting effects of myristic acid. This novel combination exhibited significant reductions in proteinuria and UACR in multiple FSGS animal models, along with improvements in kidney pathology including reduced glomerular sclerosis and tubular ectasia. The combination demonstrated synergistic therapeutic effects targeting inflammation, fibrosis, and disease progression.

These breakthroughs result from Delta4's cutting-edge Hyper-C platform, which analyzes vast biomedical datasets to identify subtle molecular relationships between diseases and drugs. The platform's ability to predict mechanisms of action and therapeutic efficacy was instrumental in repositioning clopidogrel and discovering the synergistic potential of the Saro+Myr combination. Delta4 is collaborating with partners to advance these compounds into clinical trials, expecting the trials to replicate the success observed in preclinical studies. For more information, visit https://delta4.ai/.